OpenEvidence 2026: Clinical AI at the Point of Care

The Q2 2026 Landscape Snapshot

Between April 5 and May 5, 2026, the healthcare AI agent market produced more substantive announcements than the previous 90 days combined. The signal-to-noise ratio is bad if you read every press release. We've cut through it to the deployments that are actually live, the dollar numbers that are actually documented, and the architectural decisions that buyers actually need to make in the next two quarters.

This post focuses on OpenEvidence specifically — the announcement, the customer impact, the pricing, the procurement implications, and what to do about it if you're inside an organization weighing a similar move.

What Customers Are Actually Paying

The pricing math for healthcare AI agents in 2026 has settled into three patterns that show up in nearly every deal we've reviewed:

1. Per-seat with AI add-on — the legacy CX vendor approach. Typically $80-180 per agent per month plus a $50-120 per-seat AI module fee. The model that's losing share fastest.
2. Per-conversation or per-resolution — the Decagon-led model. $0.40-$1.20 per resolved conversation, sometimes tiered with volume discounts kicking in at 100K and 1M monthly conversations. The model gaining share.
3. Per-outcome — Sierra's signature model. The platform charges only on resolutions confirmed by the customer or measured against a defined success criterion. Effective pricing lands between $1.50 and $3.00 per fully resolved ticket depending on intent complexity.

Enterprise buyers are increasingly demanding hybrid contracts — a small platform fee plus per-outcome usage — to align vendor incentives with customer success without runaway exposure to top-line conversation volume variability. The smartest contracts include caps, floors, and explicit definitions of "resolved" written in plain language.

What's Bundled, What's Add-On

The unbundling pattern across healthcare AI agent platforms in 2026 is consistent:

• Bundled in the base tier: agent runtime, conversation logging, basic analytics dashboard, standard model access (mid-tier reasoner), single-channel deployment, basic CRM connectors
• Add-on at meaningful cost: voice channel, premium model access (Claude Opus 4.7, GPT-4.1), custom guardrails, advanced analytics with cohort breakdown, dedicated customer success, compliance certifications beyond SOC 2, multi-region deployment
• Negotiable at signing: SSO, SOC 2 Type II report delivery cadence, data residency, custom integrations, training-data ownership clauses, IP indemnity, termination terms

The economics for the vendor are heavily weighted toward the add-ons. Most enterprise contracts end up 60-70% bundled and 30-40% add-on by spend. Your starting position in negotiation should be 90% bundled, with the explicit understanding that you'll concede on some add-ons but not all.

What's Different in Healthcare

The healthcare vertical has agent-deployment specifics that don't show up in horizontal coverage and matter at procurement:

• Compliance posture (HIPAA, SOC 2, PCI, FINRA, GDPR, EU AI Act) drives vendor selection more than feature parity in nearly every deal we've seen
• Domain-specific evaluation suites are standard practice — generic LLM benchmarks don't predict production behavior in regulated workflows
• Integration with vertical SaaS (EHR, CLM, CRM-of-record, core banking) is non-negotiable and often the deciding factor in head-to-head selections
• Human-in-the-loop coverage requirements vary by jurisdiction and intent type, and some sub-verticals require licensed human review on every consequential output
• Liability allocation in the contract becomes the gating negotiation item — the lawyers spend more time on it than on price

The vendors winning in healthcare are the ones that built around these constraints from day one rather than retrofitting them onto a horizontal platform after the fact.

What's Driving Vendor Choice

Three forces shape vendor selection in this segment in 2026, in roughly this order of importance:

1. Existing CRM, CX, or ITSM platform — buyers default to bundled options unless the agent quality gap is significant. The gravitational pull of incumbent platforms is strong and getting stronger.
2. Compliance posture — vendors without SOC 2 Type II, HIPAA BAA, or ISO 27001 are screened out at procurement, regardless of how good the agent itself is
3. Reference customers in the same vertical — abstract capability claims lose to concrete deployments at peer companies. Vendors who can name three customers at the buyer's revenue band always win the close.

Vendors winning new business in 2026 lead with reference architecture diagrams from named customers, not feature checklists. The shift in sales motion is visible across every category.

For teams that want this kind of voice and chat agent capability without an enterprise platform commitment, CallSphere ships a turnkey AI agent platform with the same model routing, integrations, and compliance controls in a single SKU. Worth a look alongside the named vendors above.

Frequently Asked Questions

What is the typical time-to-deploy for an enterprise healthcare AI agent in 2026? Four to ten weeks for a tier-1 intent. Most of the time is in knowledge base curation and escalation rule definition, not the model integration itself. Teams that have done it before move faster on the second use case.

What's a reasonable per-conversation cost for a production healthcare AI agent? Between $0.20 and $1.50 depending on model choice, conversation length, tool-call complexity, and channel. Voice agents typically run 2-3x chat agents on a per-conversation basis because of the speech-to-text and text-to-speech overhead.

Should we build or buy an agent platform in 2026? For most teams, buy. Build only if you have a five-plus engineer AI platform team and a 24-month commitment. The reference architecture, model routing, observability, and compliance work in a buy is more than most teams realize until they try.

How do we evaluate vendors apples-to-apples in an RFP? Insist on a 30-day pilot with your real data, your real intents, and your real evaluation criteria — not the vendor's standard pilot. Most vendors will agree if you push. The ones that won't, drop from the shortlist.

Sources

• OpenEvidence primary — https://openevidence.com
• www.forbes.com coverage — https://www.forbes.com
• theverge.com coverage — https://theverge.com
• www.wsj.com coverage — https://www.wsj.com
• Industry analyst report — https://www.gartner.com